ClinicalTrials.gov record
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00058292

Public ClinicalTrials.gov record NCT00058292. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 24, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Trial Combining IDEC-Y2B8 And High-Dose Beam Chemotherapy With Hematopoietic Progenitor Cell Transplant In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma

Study identification

NCT ID
NCT00058292
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Northwestern University
Other
Enrollment
44 participants

Conditions and interventions

Conditions

Interventions

  • Carmustine Drug
  • cytarabine Drug
  • etoposide Drug
  • filgrastim Biological
  • melphalan Drug
  • peripheral blood stem cell transplantation Procedure
  • rituximab Biological
  • yttrium Y 90 ibritumomab tiuxetan Radiation

Drug · Biological · Procedure + 1 more

Eligibility (public fields only)

Age range
17 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2000
Primary completion
May 31, 2006
Completion
Feb 28, 2009
Last update posted
May 31, 2012

2000 – 2009

United States locations

U.S. sites
3
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
Hematology-Oncology Associates of Illinois Chicago Illinois 60611-2998
Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago Illinois 60611-3013
Mayo Clinic Cancer Center Rochester Minnesota 55905

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00058292, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 31, 2012 · Synced Apr 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00058292 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →